cyrilzakka/clinical-trials huggingface dataset:
Diagnosis of Fatty Liver with Outpatient Ultrasound

This study will evaluate whether ultrasound performed during outpatient visit is effective in early diagnosis of fatty liver.

All patients presenting to dedicated hepatology clinic with concern for fatty liver will be evaluated by ultrasound. This will be compared with standard imaging performed for this condition. The data will be compared for effectiveness of outpatient evaluation with dedicated imaging currently practiced

Eligibility Criteria:
Inclusion Criteria:

* all patients presenting to dedicated clinic

Exclusion Criteria:

* presence of ascites, inability to give consent to have study
Clinical Comparison of Pain Score of Needleless Jet Injector and Conventional Needle Injection for Teeth Extraction Anesthesia (Split Mouth Technique).

Dental anesthesia with needle injection cause fear and anxiety in patients about the dental procedures. Therefore, less painful anesthesia alternatives like needleless anesthesia devices to reduce the negative sensation of pain and fear that is always associated with traditional local anesthesia needle injection.

The jet injector with INJEX is a needleless injector system that injects the local anesthesia solution into the tissues through a pressure. This research aims to compare the pain score of jet injector with INJEX and traditional local anesthesia needle injection for teeth extraction.

Method:

50 patients visiting DOW Ojha Hospital, who needs extraction of bilateral teeth will be included in this study. Data collection approval will be taken from Institutional Review Board (IRB) of DUHS.

Complete procedure, study purpose and pain scale will be explained to patients and they will be told that information will be utilized for only research purpose and after that permission will be taken from participants.

After taking history, quadrants will be divided; one for local anesthesia by the Jet Injector with INJEX and one for traditional local anesthesia needle injection.

After that local anesthesia with Jet Injector INJEX will be given to one side and traditional local anesthesia needle injection will be given to other site for teeth extraction. Then principle investigator will examine the patient pain through the pain scale (Visual Analog Scale) of this study and supervisor will confirm it.


Eligibility Criteria:
INCLUSION CRITERIA:

* 18-24 years old patient
* Patients having permanent dentition who require bilateral anterior or premolar teeth extraction
* Orthodontic patients who requires bilateral extraction of premolars
* Patients who give informed consent to take part in study

EXCLUSION CRITERIA:

* Patients with local anesthesia allergy
* Patients with localized inflammation/ localized abscess/tenderness at site of injection
* Patients who do not give informed consent to take part in study
The Effect of Parecoxib Sodium Intravenous Patient-controlled Analgesia in Laparotomic Liver Resection

The investigators hypothesized that using new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) would significantly improve postoperative pain control compare to conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline). This prospective randomized controlled trial was designed to evaluate the benefit of new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for postoperative analgesia after laparotomic liver resection.


Eligibility Criteria:
Inclusion Criteria:

Patients need laparotomic liver resection.

Exclusion Criteria:

Patients with contraindications to spinal anesthesia or intrathecal morphine, difficulty understanding passive cutaneous anaphylaxis, a history of drug dependence or chronic pain, body mass index greater than 35 kg/m2, or history of sleep apnea were excluded from this study.
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine

a multicentre phase IV study to collect evidence that a doravirine-based regimen can be safely and effectively administered to virologically suppressed HIV-infected patients undergoing bariatric suregery.


Eligibility Criteria:
Inclusion Criteria:

* HIV-infected
* VL suppressed \<40c/ml for at least 6 months, blips are allowed
* planned to have bariatric surgery (gastric bypass or gastric sleeve)
* Able to sign informed consent
* Age \> or equal to 18 years
* Using doravirine for at least 4 weeks prior to BS with VL \< 40 copies/mL prior to the surgery

Exclusion Criteria:

* History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation
* Requires or is anticipated to require any of the prohibited medications known to contradict/interact with doravirine
* Has significant hypersensitivity or other contraindication to doravirine
* Creatinine clearance \<40 ml/min
* Severe liver dysfunction (Diagnosed liver cirrhosis: Child-Pugh C)
* Pregnancy or planning to be pregnant during first 6 months postbariatric surgery.
Sublingual Versus Intranasal Administration of Dexmedetomidine for Sedation of Children Undergoing Dental Treatment

The aim of this study is to assess the efficacy of Dexmedetomidine drug either used sublingually or intranasally in managing healthy children during dental treatment

Each child should fulfill the requirements of having a dental condition which needs treatment in two dental sessions, where each session should not exceed thirty minutes. At the first visit ,either sublingual or intranasal Dexmedetomidine will be used, while at the second visit the alternate route will be implemented in a cross-over design. At least one week interval between the two visits will be secured.

Eligibility Criteria:
Inclusion Criteria:

* Frankl behavior rating score 2.
* ASA I physical status.
* Dental intervention under local anesthesia not requiring more than 30 minutes.
* No previous dental experience.
* Parent/guardian written consent.

Exclusion Criteria:

* Dental treatment indicated requiring general anesthesia.
* Mouth breathers.
* Patients with acute upper respiratory illness.
* Medically compromised patients.
* Cognitively impaired patients.
Validity of AI in Treatment of the Musculoskeletal Conditions by Vifive

The purpose of this study is to evaluate the efficacy of the 12-week ViFive program, a vision-based artificial intelligent digital care plan for chronic knee pain. ViFive digital care plan is delivered by a physical therapy team consisting of physical therapists and a personal coach. We aim to understand the safety and efficacy of this vision artificial intelligent based home exercise program.

This study is recruiting patients who present with knee osteoarthritis and shoulder adhesive capsulitis through evaluation by the treating physician. A brief physical functional assessment will be conducted to ensure eligibility and assess for any safety concerns (e.g., minimum strength and capability to conduct basic rehabilitation exercises).

Once subject is enrolled and device is distributed and set up, participants will follow and complete the VIFive program on the device.

ViFive DCP (Digital Care Program) is a highly structured, protocolized, and individually tailored intervention consisting of personalized exercise therapy modules. ViFive DCP is delivered by a physical therapy team consisting of DPTs and a personal coach. The DCP consists of ten modules and its advancement will be determined by each patient's progress after the treatment team's review every week. The primary aim of ViFive DCP is to assist patients in recovering their appropriate daily physical activity level by strengthening the knee and educating proper interpretation of sensation rather than pain. ViFive DCP represents a mobile intervention platform utilizing vision-AI. Vision AI enables objective and precise exercise prescription along with transparent patient monitoring. As a platform, there is an interface for patients and clinicians. Each module consists of a specific exercise treatment plan, educational articles, and instructions to promote changes in daily life. Each of these modules has specific goals, and patients are able to follow a predefined sequence of modules. ViFive DCP includes illustration, voice guidance, and pose correction features of AI coach. During treatment, patients have regular contact with their personal coach through a message functioning (e.g., exercise progress, answers to questions, patient receives feedback from the coach, can ask the coach questions, etc). The coach provides continuous feedback on completed tasks and responds to concerns the patient may have. Weekly feedback on progress is also provided. In total, the coach spends approximately 12 hours per patient throughout treatment.

After completion of the program, device will be returned.

Participants are to complete questionnaires, consisting of KOOS, VAS, and surgery interest at baseline, 3-month, and 6-month. VAS will be used to assess changes in pain level. KOOS will be used to assess knee functional outcome.

Eligibility Criteria:
Inclusion Criteria:

* 1.Age 18-60 years old
* Diagnosis of adhesive capsulitis or
* Diagnosis of knee osteoarthritis

Exclusion Criteria:

* Age \<18 or \>60 years old
* acute injuries or recent surgeries to the knee or shoulder
Effect of Therapeutical Paraffin in the Malleability of Burned Skin

Effect of therapeutical paraffin wax bath in the malleability of burned skin

The altered biomechanical properties of the skin entail limitation of movement, it have been important the statement of resources aimed at increasing skin suppleness. The objective of the study is to evaluate the effect of therapeutic paraffin in biophysical characteristics of the burned skin with or without scar hypertrophic. For this, 60 volunteers will be evaluated in the age group of 18-60 years, of both sexes, with deep second degree and third degree burns and evaluated areas submitted to therapeutic procedures, divided evenly into scar areas and normal skin. Applications will be set randomly by lot, with cross design (cross-over), and a minimum interval of seven days (wash-out) of the activities. The biophysical and biomechanical parameters of the skin will be assessed noninvasively by Cutometer of the model (MPA) 580, device to measure elasticity of the upper skin layer using negative pressure, and the durometer, measure hardness of the skin, before, immediately after 0, 10, 20 and 30 minutes of intervention with therapeutic paraffin in different procedures (number of layers and thermal insulation). Sociodemographic, clinical and surgical data of the volunteers will be evaluated by SPSS 15 (Statistical Analysis Software). The normality of the data will be verified by the Shapiro-Wilk test, and the effect of therapeutic procedures over time evaluated by the Friedman test (intragroup) and the test Kruskal-Wallis post hoc Dunn for comparisons between different funds (intergroup), p \<0.05, will evaluated by software SPSS.

Eligibility Criteria:
Inclusion Criteria:

* Will be included in the study individuals who were victims of 2 deep burns or 3rd grade being subjected to grafting autogenous procedures, with or without the presence of hypertrophic scar, normal skin of individuals, ie without tissue damage and to agree to sign the term free and informed consent.

Exclusion Criteria:

* They will be included in this study individuals with diseases or deformities that affect the structure and function of the skin.
Prevalence of Tapia's Syndrome in Weaning Unit

Tapia syndrome is a rare and poorly understood pathology. It is defined by a concomitant attack of the recurrent (branch of X) and hypoglossal (XII) nerves of peripheral or central origin. It is characterized by the paralysis of a vocal cord and the ipsilateral half of tongue. This damage is most often unilateral but it can also be bilateral. It results in dysphonia and swallowing disorders.

Tapia syndrome is a rare and poorly understood pathology. To date, less than 100 cases have been described in the literature. Previous works are mainly case reports and literature reviews. No prevalence study has been performed to date. Furthermore, disagreements persist regarding the semiology. Indeed, the involvement of the soft palate is not always described.

The main aim of this study was to determine the prevalence of Tapia syndrome in patients admitted to weaning unit after prolonged (\>48h) orotracheal intubation in the ICU.

The secondary objectives are to:

* Describe the clinical semiology of Tapia syndrome : lingual involvement, soft palate involvement, impairment of phonation and swallowing ;
* Describe the paraclinical features of Tapia syndrome: recurrent involvement, laryngeal and lingual involvement;
* Identify factors associated with Tapia's syndrome

Eligibility Criteria:
Inclusion Criteria:

* Hospitalized in weaning unit
* Duration of orotracheal intubation in the ICU greater than 48 hours;
* Glasgow score greater than or equal to 13 ;
* Patient at least 18 years of age at the time of inclusion;
* Affiliation with a social security system or beneficiary of such a system ;
* Oral, free, informed and express consent of the patient.

Exclusion Criteria:

* Known history of ENT or neurological pathologies (stroke, head trauma, neurodegenerative disease, brain tumor, ENT cancer);
* Known tumors in the vicinity of the X-nerve pathway;
* Ortner's syndrome (left recurrent nerve compression through the left atrium in mitral stenosis);
* Left lung cancer with subaortic lesion;
* History of cervical adenopathy compressing the X nerve;
* Presence of a cervical or cerebral abscess;
* 24-hour ventilated patient;
* Refusal of the patient or designated trusted person to participate in the study;
* Person subject to a safeguard of justice measure ;
VADOplex Critical Limb Ischemia Study

In patients with critical limb ischemia (CLI) and foot ulcers wound healing is an important goal which can normally only be achieved after sufficient treatment of the underlying ischemia (revascularization either by an operation, e. g. bypass, or a catheter intervention). After successful revascularization everything should be done to improve wound healing because this regularly takes weeks up to several months. One possibility to speed up healing could be treatment with the VADOplex device which delivers an automatic intermittent painless compression of the sole of the foot thereby increasing perfusion of the leg. This system can be easily operated by patients themselves and at home.

Our goal is to prove that the VADOPlex system accelerates healing up and improves quality of life.


Eligibility Criteria:
Inclusion Criteria:

* signed informend consent
* peripheral artery disease Fontaine IV (equals Ruterford 5 and 6) with or without neuropathy
* foot lesion stage 1 - 4 analogous to 4 Wagner classification of the diabetic foot
* secondary wound healing if previous surgical wound treatment
* previous interventional and/or surgical revascularisation
* age above 18
* hosptalized to the beginning of the study

Exclusion Criteria:

* primary wound healing if previous surgical wound treatment
* uncontrolled local or systemic infection
* renal failure on dialysis
* inability or insufficient help to operate the VADOplex system
* wound dressings that lead to insufficient compression by the VADOplex system (e.g. total contact cast for offloading)
* wounds of other than ischemic or neuro-ischemic origin
Treatment of Complaints Following Sports Injuries With Traditional Chinese Medicine

The purpose of this observational study is to investigate the treatment of complaints following sports injuries with Traditional Chinese Medicine by therapists in Switzerland.

In Switzerland, still very little is known about the treatment with TCM (acupuncture, Chinese medicinal therapy, Tuina massage, nutrition, qigong) under everyday conditions. The importance of non-medical therapists in the healthcare system is rarely investigated. It is likely that patients with chronic injuries use several therapies (including conventional medicine) in a pragmatic way. They may apply TCM either due to primary preference or because other forms of therapy fail to produce satisfactory results.

There is evidence from randomized controlled trials and systematic reviews that acupuncture can be effective in the treatment of acute and chronic back pain, chronic shoulder pain and ankle sprains.

Randomized controlled trials usually investigate a single TCM method, in which therapists or physicians are limited in the selection of acupuncture points or herbal formulas. This does not reflect the complex practice, where several TCM methods and auxiliary techniques are combined.

The investigators aim to investigate in a prospective observational study how complaints following sports injuries are treated by non-medical TCM therapists in Switzerland under everyday conditions.

Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* minimum of 3 hours sports per week
* complaints following sports injury
* first TCM treatment for this complaint

Exclusion Criteria:

* rheumatic disease
* arthrosis
* previous TCM treatment for this complaint
Comparison of RIRS Versus PCNL Methods, According to Postoperative Pain and Analgesic Demand in 2 to 4 cm Renal Stones

Purpose: to investigate the postoperative outcomes of Retrograde intrarenal surgery versus percutaneous nephrolithotomy in 2 to 4 cm kidney stones.


Eligibility Criteria:
Inclusion Criteria:

* The patients who have 2 to 4 cm kidney stones
* ASA score within 1 to 3

Exclusion Criteria:

* Previous surgical treatment including SWL
* Congenital abnormalities
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of Verinurad and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or cardiovascular status of patients with hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).

Evidence shows independent associations between elevated serum uric acid (sUA) and the risk of hypertension, myocardial infarction (MI), chronic kidney disease (CKD), T2DM, heart failure (HF), and metabolic syndrome, including obesity. Gout is associated with an increased risk of all-cause death, as well as cardiovascular death. The causal relationship between elevated sUA, gout, and these disease outcomes remains to be proven.

Verinurad (RDEA3170), is a novel Urate Transporter 1 (URAT1) inhibitor in Phase II development. Verinurad combined with the xanthine oxidase (XO) inhibitor febuxostat has been shown to lower sUA in patients with recurrent gout in Phase II studies by \>80%. The extensive lowering of sUA delivered by the combination presents a unique opportunity to explore whether intensive urate lowering therapy can improve kidney and/or cardiac health.

This study will assess if intensive serum urate lowering therapy, more potent than ever explored before in the chronic out-patient setting, can improve chronic kidney or cardiac function in the study population.

In order to maximize the scientific value of the study and minimize the risk for systemic biases a parallel group, double blind, randomized design will be utilized.

The study will recruit patients with hyperuricemia and presenting with albuminuria.

Hyperuricemic patients are expected to benefit more from urate lowering, and albuminuria at baseline is required, as the primary objective of the study will be to assess changes in albuminuria.

Patients are also required to be diagnosed with T2DM. Patients with T2DM frequently exhibit changes in cardiac function detectable using magnetic resonance imaging (MRI) that represents an early, pre-symptomatic state of HF. By limiting recruitment to patients with T2DM and by performing MRI at baseline and 6 months of therapy, the study will deliver insights into whether or not intensive urate lowering therapy can positively affect not only chronic kidney disease, but also cardiac disease.

Eligibility Criteria:
Inclusion Criteria:

* Serum Uric Acid ≥6.0 mg/dL
* eGFR ≥30 mL/min/1.73 m2
* UACR between 30 mg/g and 3500 mg/g inclusive
* Diagnosed with T2DM

Exclusion Criteria:

* Treated with any drug for hyperuricemia in the 6 months preceding randomization.Drugs for hyperuricemia include all XO inhibitors (allopurinol, febuxostat and topiroxostat) and URAT1 inhibitors (lesinurad, verinurad, probenecid, and benzbromarone)
* Prior history of gout, unless prophylaxis therapy isn't required
* Patients who are pregnant, lactating, or planning to become pregnant
* Patients unsuitable or unable to undergo MRI assessment
Painless Sharp Wound Debridement With Lidocaine-23%-Tetra-caine-7% Gel Versus EMLA 5% Cream

In a single-blind, crossover, randomized, controlled trial with 40 participants we aim to demonstrate superior anaesthetic efficacy of lidocaine-23%-tetracaine-7% (IMP2) gel over EMLA 5% cream (IMP1) at comparable safety in sharp wound debridement of chronic leg ulcers.

This is a monocentric investigator initiated trial conducted in the University Hospital Zurich.

In this longitudinal trial, participants receive a sequence of different treatments (treatments on different days) and therefore are randomly assigned to one of two treatment sequences. One-half of participants will first receive IMP1 (first treatment visit, randomized) and then IMP2 (second treatment visit, crossover); the other half of participants the reverse sequence (first treatment visit: IMP2, second treatment visit: IMP1).

Primary Objective: We want to show that IMP 2 (lidocaine-23%-tetracaine-7% gel) is more effective in pain reduction than IMP 1 (EMLA® 5% cream) in sharp wound debridement.


Eligibility Criteria:
Inclusion Criteria:

* Participants between 18 years and 90 years
* Chronic leg ulcer(s) (duration \> 4 weeks) with biofilm or necrotic layers which require consecutive sharp debridement for at least two times (of the same ulcer)
* Minimal ulcer area of 1 cm2
* Leg ulcer has to enter into one of the following well defined aetiologies: venous, mixed venous-arterial, arterial, hypertensive ischemic leg ulcer (Martorell), vasculitic, ecthyma (covering \>90% of all observed leg ulcers)
* Informed consent as documented by signature and being able to follow the study protocol (cognition)
* Proficiency in German, oral and written information

Exclusion Criteria:

* Women who are pregnant or breastfeeding (Women of childbearing potential need to perform a pregnancy test (urine test) within 24 hours prior to the study intervention and need at least one simple acceptable contraceptive method)
* Participants with hypersensitivity or allergy to lidocaine, prilocaine, tetracaine or auxiliary supplies contained in either EMLA® 5% cream or lidocaine-23%-tetracaine-7% gel.
* Participants with peripheral neuropathy (over 4/10 insensitive points with Semmes monofilament) are excluded due to disturbed pain perception, which could potentially influence the results.
* Participants that were previously included in this clinical trial
* Participants with a total wound area larger than 200 cm2